Factor VIII inhibitors in hemophilia A: Rationale and latest evidence

Therapeutic Advances in Hematology

Volumn 4, Issue 1, 2013, Pages 59-72

  Witmer, Char ^a   Young, Guy ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

FVIII; FVIII alloantibodies; hemophilia A; immune tolerance; inhibitors; risk factors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; CYTOKINE; IMMUNOLOGIC FACTOR; INTERLEUKIN DERIVATIVE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

DRUG MEGADOSE; DRUG TOLERANCE; ERADICATION THERAPY; ETHNIC DIFFERENCE; GENE MUTATION; GENETIC RISK; HEMOPHILIA A; HEMOSTASIS; HEREDITY; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORBIDITY; MULTICENTER STUDY (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE;

EID: 84993661361     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712464509     Document Type: Article

References (119)

1. Addiego J. Kasper C. Abildgaard C. Hilgartner M. Lusher J. Glader B. et al. (1993) Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 342: 462–464.
2. Aledort L. Dimichele D. (1998) Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 4: 68.
3. Astermark J. (2006) Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 12(Suppl. 3): 52–60.
4. Astermark J. Berntorp E. White G. Kroner B. (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 7: 267–272.
5. Astermark J. Donfield S. Di Michele D. Gringeri A. Gilbert S. Waters J. et al. (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109: 546–551.
6. Astermark J. Oldenburg J. Carlson J. Pavlova A. Kavakli K. Berntorp E. et al. (2006 a) Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 108: 3739–3745.
7. Astermark J. Oldenburg J. Pavlova A. Berntorp E. Lefvert A. (2006 b) Polymorphisms in the IL 10 but not in the IL 1 beta and IL 4 genes are associated with inhibitor development in patients with hemophilia A. Blood 107: 3167–3172.
8. Bafunno V. Santacroce R. Chetta M. D'Andrea G. Pisanelli D. Sessa F. et al. (2010) Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A. Haemophilia 16: 469–473.
9. Berntorp E. Astermark J. Carlborg E. (2000) Immune tolerance induction and the treatment of hemophilia. Malmo protocol update. Haematologica 85(10 Suppl.): 48–50; discussion 50-51.
10. Bray G. Gomperts E. Courter S. Gruppo R. Gordon E. Manco-Johnson M. et al. (1994) A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 83: 2428–2435.
11. Bril W. MacLean P. Kaijen P. van den Brink E. Lardy N. Fijnvandraat K. et al. (2004) HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg 593 to Cys mutation. Haemophilia 10: 509–514.
12. Brown T. Lee W. Joshi A. Pashos C. (2009) Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia 15: 911–917.
13. Buchanan G. Kevy S. (1978) Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies. Pediatrics 62: 767–774.
14. Carpenter S. Michael Soucie J. Sterner S. Presley R. (2012) Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia 18: e260–e265.
15. Chalmers E. Brown S. Keeling D. Liesner R. Richards M. Stirling D. et al. (2007) Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 13: 149–155.
16. Coppola A. Margaglione M. Santagostino E. Rocino A. Grandone E. Mannucci P. et al. (2009) Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 7: 1809–1815.
17. Darby S. Keeling D. Spooner R. Wan Kan S. Giangrande P. Collins P. et al. (2004) The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2: 1047–1054.
18. Dasgupta S. Repesse Y. Bayry J. Navarrete A. Wootla B. Delignat S. et al. (2007) VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 109: 610–612.
19. Dazzi F. Tison T. Vianello F. Radossi P. Zerbinati P. Carraro P. et al. (1996) High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 93: 688–693.
20. Dimichele D. (2009) The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 15: 320–328.
21. Di Minno M. Di Minno G. Di Capua M. Cerbone A. Coppola A. (2010) Cost of care of haemophilia with inhibitors. Haemophilia 16: e190–e201.
22. Eckhardt C. Kamphuisen P. Fijnvandraat K. (2009 a) Inhibitors of factor VIII in hemophilia. N Engl J Med 361: 309; author reply 310.
23. Eckhardt C. Menke L. van Ommen C. van der Lee J. Geskus R. Kamphuisen P. et al. (2009 b) Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild / moderate hemophilia A. J Thromb Haemost 7: 930–937.
24. Ehrenforth S. Kreuz W. Scharrer I. Linde R. Funk M. Gungor T. et al. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339: 594–598.
25. Franchini M. Favaloro E. Lippi G. (2010) Mild hemophilia A. J Thromb Haemost 8: 421–432.
26. Franchini M. Lippi G. (2011) Immune tolerance induction for patients with severe hemophilia A: a critical literature review. J Thromb Thrombolysis 32: 439–447.
27. Franchini M. Mengoli C. Lippi G. Targher G. Montagnana M. Salvagno G. et al. (2008) Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis. Haemophilia 14: 903–912.
28. Franchini M. Tagliaferri A. Mengoli C. Cruciani M. (2012) Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 81: 82–93.
29. Fulcher C. de Graaf Mahoney S. Roberts J. Kasper C. Zimmerman T. (1985) Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A 82: 7728–7732.
30. Fulcher C. de Graaf Mahoney S. Zimmerman T. (1987) FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 69: 1475–1480.
31. Fulcher C. Lechner K. de Graaf Mahoney S. (1988) Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 72: 1348–1356.
32. Gallucci S. Matzinger P. (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13: 114–119.
33. Giles A. Verbruggen B. Rivard G. Teitel J. Walker I. (1998) A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII / IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 79: 872–875.
34. Gilles J. Arnout J. Vermylen J. Saint-Remy J. (1993) Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 82: 2452–2461.
35. Gouw S. van den Berg H. Le Cessie S. van der Bom J. (2007 a) Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 5: 1383–1390.
36. Gouw S. van den Berg H. Oldenburg J. Astermark J. de Groot P. Margaglione M. et al. (2012) F 8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 119: 2922–2934.
37. Gouw S. van der Bom J. Marijke van den Berg H. (2007 b) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109: 4648–4654.
38. Grancha S. Navajas R. Maranon C. Paradela A. Albar J. Jorquera J. (2011) Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates. Haemophilia 17: 709–710.
39. Gringeri A. (2007) VWF / FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 13(Suppl. 5): 73–77.
40. Gringeri A. Fischer K. Karafoulidou A. Klamroth R. Lopez-Fernandez M. Mancuso E. (2011 a) Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 17: 630–635.
41. Gringeri A. Lundin B. von Mackensen S. Mantovani L. Mannucci P. (2011 b) A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 9: 700–710.
42. Gringeri A. Mantovani L. Scalone L. Mannucci P. (2003) Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 102: 2358–2363.
43. Hay C. Di Michele D. (2012) The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 119: 1335–1344.
44. Hay C. Ludlam C. Colvin B. Hill F. Preston F. Wasseem N. et al. (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 79: 762–766.
45. Hay C. Ollier W. Pepper L. Cumming A. Keeney S. Goodeve A. et al. (1997) HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 77: 234–237.
46. Hay C. Palmer B. Chalmers E. Liesner R. Maclean R. Rangarajan S. et al. (2011) Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 117: 6367–6370.
47. Haya S. Lopez M. Aznar J. Batlle J. (2001) Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 7: 154–159.
48. Hilgartner M. Knatterud G. (1983) The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 61: 36–40.
49. Hironaka T. Furukawa K. Esmon P. Fournel M. Sawada S. Kato M. et al. (1992) Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 267: 8012–8020.
50. Hoots W. Ebbesen L. Konkle B. Auerswald G. Roberts H. Weatherall J. et al. (2008) Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 14: 466–475.
51. Ingerslev J. Sorensen B. (2011) Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol 155: 256–262.
52. Iorio A. Halimeh S. Holzhauer S. Goldenberg N. Marchesini E. Marcucci M. et al. (2010) Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 8: 1256–1265.
53. Kasper C. Aledort L. Aronson D. Counts R. Edson J. van Eys J. et al. (1975) Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34: 612.
54. Kempton C. Abshire T. Deveras R. Hoots W. Gill J. Kessler C. et al. (2012) Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 18: 798–804.
55. Kempton C. Soucie J. Miller C. Hooper C. Escobar M. Cohen A. et al. (2010) In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost 8: 2224–2231.
56. Kempton C. White G. (2009) How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 113: 11–17.
57. Konkle B. Ebbesen L. Erhardtsen E. Bianco R. Lissitchkov T. Rusen L. et al. (2007) Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 5: 1904–1913.
58. Kono H. Rock K. (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8: 279–289.
59. Kroner B. (1999) Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 77(Suppl. 1): 33–37.
60. Kurczynski E. Penner J. (1974) Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 291: 164–167.
61. Kurnik K. Bidlingmaier C. Engl W. Chehadeh H. Reipert B. Auerswald G. (2010) New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 16: 256–262.
62. Lacroix-Desmazes S. Dimitrov J. Repesse Y. (2009) Inhibitors of factor VIII in hemophilia. N Engl J Med 361: 308; author reply 310.
63. Lee C. Berntorp E. Hoots W. (2005) Textbook of Hemophilia. 1st edn. Malden, MA: Blackwell Publishing.
64. Leissinger C. Gringeri A. Antmen B. Berntorp E. Biasoli C. Carpenter S. et al. (2011 a) Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 365: 1684–1692.
65. Leissinger C. Kruse-Jarres R. Granger S. Konkle B. Ragni M. Journeycake J. et al. (2011 b) Phase II trial of rituximab in the treatment of inhibitors in congenital hemophilia A: results of the RICH study. Blood (ASH Annual Meeting Abstracts) 118: 27.
66. Lenk H. (2000) The German Registry of immune tolerance treatment in hemophilia – 1999 update. Haematologica 85(10 Suppl.): 45–47.
67. Ling M. Duncan E. Rodgers S. Street A. Lloyd J. (2003) Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 1: 2548–2553.
68. Lollar P. (2004) Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2: 1082–1095.
69. Lorenzo J. Lopez A. Altisent C. Aznar J. (2001) Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 113: 600–603.
70. Lozier J. Rosenberg P. Goedert J. Menashe I. (2011) A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia 17: 641–649.
71. Lusher J. Arkin S. Abildgaard C. Schwartz R. (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 328: 453–459.
72. Lusher J. Roberts H. Davignon G. Joist J. Smith H. Shapiro A. et al. (1998) A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 4: 790–798.
73. Maclean P. Richards M. Williams M. Collins P. Liesner R. Keeling D. et al. (2011) Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 17: 282–287.
74. Manco-Johnson M. Abshire T. Shapiro A. Riske B. Hacker M. Kilcoyne R. et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535–544.
75. Mannucci P. Gringeri A. Peyvandi F. Santagostino E. (2007) Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 13(Suppl. 5): 65–68.
76. Mannucci P. Mancuso M. Santagostino E. (2012) How we choose factor VIII to treat hemophilia. Blood 119: 4108–4114.
77. Mariani G. Scheibel E. Nogao T. Kasper C. Ewing N. Mauser-Bunschoten E. et al. (1994) Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 31(2 Suppl. 4): 62–64.
78. Matzinger P. (2002) The danger model: a renewed sense of self. Science 296: 301–305.
79. Mauser-Bunschoten E. Den Uijl I. Schutgens R. Roosendaal G. Fischer K. (2012) Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia 18: 263–267.
80. Meijer P. Verbruggen B. (2009) The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 35: 786–793.
81. Miao C. (2010) Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol 3: 469–483.
82. Miller C. Benson J. Ellingsen D. Driggers J. Payne A. Kelly F. et al. (2012) F 8 and F 9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia 18: 375–382.
83. Morfini M. Haya S. Tagariello G. Pollmann H. Quintana M. Siegmund B. et al. (2007) European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 13: 606–612.
84. Nilsson I. Berntorp E. Zettervall O. (1988) Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 318: 947–950.
85. Oldenburg J. Picard J. Schwaab R. Brackmann H. Tuddenham E. Simpson E. (1997) HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 77: 238–242.
86. Oldenburg J. Schroder J. Brackmann H. Muller-Reible C. Schwaab R. Tuddenham E. (2004) Environmental and genetic factors influencing inhibitor development. Semin Hematol 41(1 Suppl. 1): 82–88.
87. Pavlova A. Delev D. Lacroix-Desmazes S. Schwaab R. Mende M. Fimmers R. et al. (2009) Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 7: 2006–2015.
88. Peyvandi F. Lotta L. Mannucci P. (2009) Inhibitors of factor VIII in hemophilia. N Engl J Med 361: 309; author reply 310.
89. Qadura M. Othman M. Waters B. Chegeni R. Walker K. Labelle A. et al. (2008) Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. J Thromb Haemost 6: 2095–2104.
90. Qadura M. Waters B. Burnett E. Chegeni R. Bradshaw S. Hough C. et al. (2009) Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 114: 871–880.
91. Ragni M. Ojeifo O. Feng J. Yan J. Hill K. Sommer S. et al. (2009 a) Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia 15: 1074–1082.
92. Ragni M. Wu W. Liang X. Hsieh C. Cortese-Hassett A. Lu L. (2009 b) Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model. Exp Hematol 37: 744–754.
93. Rawle F. Pratt K. Labelle A. Weiner H. Hough C. Lillicrap D. (2006) Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C 2 domain. J Thromb Haemost 4: 2172–2179.
94. Rivard G. Lillicrap D. Poon M. Demers C. Lepine M. St-Louis J. et al. (2005) Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age? Haemophilia 11: 335–339.
95. Robbins D. Kulkarni R. Gera R. Scott-Emuakpor A. Bosma K. Penner J. (2001) Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol 68: 184–188.
96. Saint-Remy J. Lacroix-Desmazes S. Oldenburg J. (2004) Inhibitors in haemophilia: pathophysiology. Haemophilia 10(Suppl. 4): 146–151.
97. Santagostino E. Mancuso M. Rocino A. Mancuso G. Mazzucconi M. Tagliaferri A. et al. (2005) Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 130: 422–427.
98. Santos A. Annichino-Bizzacchi J. Ozelo M. (2009) Inhibitors of factor VIII in hemophilia. N Engl J Med 361: 309–310; author reply 310.
99. Scandella D. Mattingly M. de Graaf S. Fulcher C. (1989) Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 74: 1618–1626.
100. Scharrer I. Bray G. Neutzling O. (1999) Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 5: 145–154.
101. Schneiderman J. Nugent D. Young G. (2004) Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 10: 347–351.
102. Shapiro A. Gilchrist G. Hoots W. Cooper H. Gastineau D. (1998) Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80: 773–778.
103. Sharathkumar A. Lillicrap D. Blanchette V. Kern M. Leggo J. Stain A. et al. (2003) Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 1: 1228–1236.
104. Sjamsoedin L. Heijnen L. Mauser-Bunschoten E. van Geijlswijk J. van Houwelingen H. van Asten P. et al. (1981) The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 305: 717–721.
105. Soucie J. Evatt B. Jackson D. (1998) Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 59: 288–294.
106. Su R. Epp A. Latchman Y. Bolgiano D. Pipe S. Josephson N. (2010) Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts. Mol Ther 18: 214–222.
107. Sultan Y. (1992) Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 67: 600–602.
108. ter Avest P. Fischer K. Mancuso M. Santagostino E. Yuste V. van den Berg H. et al. (2008) Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost 6: 2048–2054.
109. van der Bom J. Mauser-Bunschoten E. Fischer K. van den Berg H. (2003) Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 89: 475–479.
110. Verbruggen B. Novakova I. Wessels H. Boezeman J. van den Berg M. Mauser-Bunschoten E. (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 73: 247–251.
111. Viel K. Ameri A. Abshire T. Iyer R. Watts R. Lutcher C. et al. (2009) Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 360: 1618–1627.
112. Vlot A. Wittebol S. Strengers P. Turenhout E. Voorberg J. van den Berg H. et al. (2002) Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618-->Ser mutation responsive to immune tolerance induction and cyclophosphamide. Br J Haematol 117: 136–140.
113. Waters B. Lillicrap D. (2009) The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 7: 1446–1456.
114. White G. Rosendaal F. Aledort L. Lusher J. Rothschild C. Ingerslev J. (2001) Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 85: 560.
115. Wight J. Paisley S. (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9: 418–435.
116. Yang G. Yao L. Lu Z. (2009) Inhibitors of factor VIII in hemophilia. N Engl J Med 361: 309; author reply 310.
117. Young G. Auerswald G. Jimenez-Yuste V. Konkle B. Lambert T. Morfini M. et al. (2011) When should prophylaxis therapy in inhibitor patients be considered? Haemophilia 17: e849–e857.
118. Young M. Inaba H. Hoyer L. Higuchi M. Kazazian H. Antonarakis S. (1997) Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene. Am J Hum Genet 60: 565–573.
119. Zakarija A. Harris S. Rademaker A. Brewer J. Krudysz-Amblo J. Butenas S. et al. (2011) Alloantibodies to factor VIII in haemophilia. Haemophilia 17: 636–640.